MetaCap

Evotec SE ADR Company Profile

NASDAQ: EVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.32-0.13 (-8.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Evotec at a glance

Evotec SE ADR (NASDAQ: EVO) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Hamburg, Germany. Evotec is led by Dr. Christian Wojczewski Ph.D. and employs about 4,379 people. The company's shares have traded publicly since 2021.

At a market capitalization of $469.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001412558, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Evotec do?

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Business description based on the company's public filings.

Company information

Legal name
Evotec SE ADR
Ticker
NASDAQ: EVO
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Christian Wojczewski Ph.D.
Employees
4,379
Headquarters
Essener Bogen 7, Hamburg, Germany
Phone
49 40 560 81 0
Website
evotec.com
IPO year
2021
Market cap
$469.11M
SEC CIK
0001412558

Companies similar to Evotec

EVO peer companies
CompanyPrice% ChgMarket capCompare
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs EVO
RZLTRezolute Inc.3.92-6.67%$465.58Mvs EVO
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs EVO
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs EVO
NGNENeurogene Inc.22.15-3.40%$458.53Mvs EVO
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs EVO
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs EVO
HELPHelus Pharma Inc.6.11-9.88%$487.68Mvs EVO

Related